One More Step for Future
Cell and Gene Therapy R&D
R&D Highlights
동종 CAR-NK 세포치료제 연구개발
Onco-therapy 세포유전자치료 플랫폼 고도화
First-in-class or Best-in-class 후보 물질 발굴
면역항암치료 적응증 확대
| Classification | Project | Research | Preclinical | Phase 1 | Phase 2 | Phase 3 | BLA |
|---|---|---|---|---|---|---|---|
| Autologous | GCC4002
(Immuncell-LC, CIK**) |
Pancreatic Cancer
Ph3 on-going
|
|||||
| GCC4002
(Immuncell-LC, CIK**) |
Liver cancer(HCC)
Approved in Korea
|
||||||
| Allogeneic | GCC4001
(AB-101, Naive NK Cell) + Rituximab |
r/r* Lymphoma
Ph1 on-going
|
|||||
| GCC4001
(AB-101, Naive NK Cell) + Rituximab |
Lupus (Autoimmune)
IND cleared by US FDA
|
||||||
| GCC4001
(AB-101, Naive NK Cell) + AFM13 |
r/r* Hodgkin Lymphoma / CD30+ Peripheral T-Cell Lymphoma
Ph2 cleared by US FDA
|
||||||
| GCC2003
(AB-201, HER2 CAR-NK) |
HER2+ Solid Cancer
Multi-regional study; IND cleared by US FDA; IND cleared in Australia and Korea
|
||||||
| GCC2004
(AB-202, CD19 CAR-NK) |
B-cell Lymphoma
|
||||||
| GCC2005
(AB-205, CD5 CAR-NK) |
T-cell Lymphoma
IND cleared by MFDS
|
||||||
* r/r : Relapsed/Refractory
** CIK, cytokine-induced killer cell
** CIK, cytokine-induced killer cell
